Sima Patel, DO
Allergy · New York, NYNPI 1912263450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 822 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AstraZeneca at 24.9% of the total. 2025 is the largest year on record at $5,817, 7.8 times the $750 reported in 2019.
Across 822 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Sanofi$4K
- GSK$3K
- Kaleo, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Novartis$868
- plus $6K from 29 others
What the payments were for
- Consulting fees$500%
- Food & beverage$20,96099%
- Education$1030%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 188 | $5,254 |
| Sanofi | 110 | $3,727 |
| GSK | 168 | $3,461 |
| Kaleo, Inc. | 54 | $1,051 |
| Regeneron Healthcare Solutions, Inc. | 39 | $1,014 |
| Novartis | 43 | $868 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $746 |
| Pfizer | 27 | $589 |
| Amgen(2 entities) | 24 | $498 |
| Teva Pharmaceuticals USA, Inc. | 22 | $468 |
| CSL Behring | 13 | $430 |
| Blueprint Medicines Corporation | 9 | $399 |
| Genentech USA, Inc. | 23 | $388 |
| LEO Pharma Inc. | 9 | $360 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $257 |
| Optinose US, Inc. | 15 | $236 |
| Biocryst US Sales Co., LLC | 9 | $208 |
| Galderma Laboratories, L.p. | 9 | $166 |
| Pharming Healthcare, Inc. | 6 | $148 |
| Stryker | 1 | $132 |
| Lilly USA, LLC | 2 | $117 |
| Hikma Pharmaceuticals USA | 7 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Alk-abello, Inc | 3 | $91 |
| Aimmune Therapeutics, Inc. | 3 | $59 |
| AbbVie | 2 | $51 |
| Boehringer Ingelheim | 1 | $31 |
| Cycle Pharmaceuticals Inc | 1 | $28 |
| Grifols USA, LLC | 1 | $25 |
| Insulet Corporation | 1 | $24 |
| Incyte Corporation | 1 | $21 |
| Covis Pharma GmbH | 1 | $21 |
| Phadia US Inc. | 1 | $17 |
| Merck | 1 | $13 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,113 in reported general payments places this provider in the 85th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $344 |
| Azelastine Hcl | 13 | $333 |
| Fluticasone Propionate | 23 | $199 |
Paid to pharmacies, not to this prescriber.
Other allergy in New York
- Mariana MarcuNew York$8K
- Gillian ShepherdNew York$7K
- Anna KochinNew York$7K
- Wellington TichenorNew York$3K
- Rushita MehtaNew York$694
- Lisa Ellman-GruntherNew York$627
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.